PsychoGenics Achieves Top Supplier Status on Scientist.com for 2023
PGI is pleased to be recognized by scientist.com as a top marketplace supplier for 2023.
PsychoGenics Announces Exclusive Global License for an IND-ready ENT1 Inhibitor for the Treatment of Neuropsychiatric Disorders
PGI Drug Discovery LLC (PsychoGenics), a phenotypic drug discovery platform company, announced that it has entered into an exclusive license agreement with Roche to obtain global development, manufacturing, and commercialization rights…
PsychoGenics Launches Updated Corporate Identity and Brand
PsychoGenics, Inc. (“PsychoGenics” or the “Company”), the leading contract research organization (CRO) specializing in the central nervous system (CNS) focused preclinical and translational drug discovery services, is proud to unveil…
AI-discovered drug shows ‘enormous potential’ to treat schizophrenia: ‘Real need for better treatment’
May 9, 2023・By Angelica Stabile・Fox News
PsychoGenics Launches eCube, a New AI-Enabled Platform for Drug Discovery
April 6, 2023・Businesswire PARAMUS, N.J.–(BUSINESS WIRE)–PsychoGenics Inc. (“PsychoGenics” or the “Company”), a leader in AI-enabled phenotypic drug discovery and preclinical CRO...
PsychoGenics highlights a long-term collaboration with the TSC Alliance on Rare Disease Day
Feb. 28, 2023 On this Rare Disease Day, we want to highlight and honor our long-term collaboration with the TSC...